ArticleJournal of the National Cancer Institute2026
Liver fat and clinical outcomes in individuals with stage I-III colon or rectal cancer.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development and external validation of a preoperative CT body composition-based model for predicting postoperative metastasis in colorectal cancer: a multicenter retrospective cohort study.Abdominal radiology (New York) · 2026Article
- Longitudinal analysis of body compositions following Roux-en-Y gastric bypass.Langenbeck's archives of surgery · 2026Article
- Preoperative CT-derived liver fat fraction and visceral adipose tissue index enhance postoperative recurrence risk stratification in colorectal cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundLiver fat accumulation has been associated with impaired colorectal cancer prognosis. Associations may differ for colon and rectal cancer due to different disease mechanisms and dissemination patterns. Here, we investigated associations between liver fat and cancer recurrence, recurrence-free survival (RFS), and overall survival (OS) among 1596 individuals with stage I-III colon or rectal cancer.
methodsWithin a prospective cohort study, we used data from adults recently diagnosed with colon (n = 1080) or rectal (n = 516) cancer. Liver fat was evaluated using routine contrast-enhanced computed tomography (CT)-scans taken at diagnosis. Cox proportional hazards regression analyses adjusted for clinical and lifestyle-related variables were used to obtain hazard ratios (HRs) and 95% confidence intervals (95% CIs).
resultsDuring a median follow-up of 6.4 and 8.8 years, 247 (15%) recurrences (12% for colon and 22% for rectal cancer) and 418 (26%) deaths (25% for colon and 29% for rectal cancer) occurred, respectively. More liver fat was associated with an increased recurrence risk (HRT3vsT1 = 1.60, 95% CI = 1.02 to 2.50), worse RFS (HRT3vsT1 = 1.45, 95% CI = 1.05 to 2.00), and OS (HRT3vsT1 = 1.67, 95% CI = 1.20 to 2.33) among individuals with colon cancer. Liver fat was not associated with recurrence (HRT3vsT1 = 0.70, 95% CI = 0.42 to 1.18), RFS (HRT3vsT1 = 0.87, 95% CI = 0.59 to 1.30), or OS (HRT3vsT1 = 1.15, 95% CI = 0.74 to 1.80) among individuals with rectal cancer.
conclusionMore liver fat was associated with poor clinical outcomes in patients with stage I-III colon cancer. Further studies are needed to confirm these findings and explore mechanistic routes linking liver fat to colon cancer prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.